Journal
JOURNAL OF CLINICAL MEDICINE
Volume 5, Issue 10, Pages -Publisher
MDPI
DOI: 10.3390/jcm5100084
Keywords
anti-PD-1; anti-PD-L1; checkpoint inhibitor; ipilimumab; esophageal cancer; gastric cancer; immunotherapy; pembrolizumab; nivolumab
Categories
Funding
- NIHR RM/ICR BRC
- National Institute for Health Research [ACF-2015-22-004] Funding Source: researchfish
Ask authors/readers for more resources
Survival for patients with advanced oesophageal and stomach cancer is poor; together these cancers are responsible for more than a million deaths per year globally. As chemotherapy and targeted therapies such as trastuzumab and ramucirumab result in modest improvements in survival but not long-term cure for such patients, development of alternative treatment approaches is warranted. Novel immunotherapy drugs such as checkpoint inhibitors have been paradigm changing in melanoma, non-small cell lung cancer and urothelial cancers. In this review, we assess the early evidence for efficacy of immunotherapy in patients with gastroesophageal cancer in addition to considering biomarkers associated with response to these treatments. Early results of Anti- Programmed Cell Death Protein-1 (anti-PD-1), anti-PD-L1 and anti-Cytotoxic T-lymphocyte assosciated protein-4 (anti-CTLA4) trials are examined, and we conclude with a discussion on the future direction for immunotherapy for gastroesophageal cancer patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available